December 5th, 2007
WBZ-4: Re-engineered Gleevec™, Reduces Cardio Risks
The powerful anti-cancer drug imatinib (Gleevec™) has been re-engineered by researchers at Rice University and the University of Texas M. D. Anderson Cancer Center.
Developed by Novartis Pharmaceuticals, Gleevec is approved by the U.S. Food and Drug Administration for the treatment of chronic myeloid leukemia (CML), Philadelphia-chromosome positive acute lymphoblastic leukemia and GIST.
The drug targets two […]
Recent Comments